You must have the patience of Jobe pierre,Between PEB and BLT i would have been pulling my hair out.Both seem to be coming right and there is no substitute for experience which i think they both have in spades.Well done
Printable View
It's been a long slow journey but they are finally getting there. As David Darling once said about the NZ DHBs "its like wading through treacle."
He also mentioned on the full year results conference call a few weeks ago that once they had set up an agreement with the Canterbury DHB , the overhead cost to PEB is very low. No sales input needed and in fact, they only need to have contact with the DHB about twice a year. No doubt the same will happen with Kaiser and other big players.
When you think of how long this has taken and the obstacles PEB have had to overcome, it means any competition is a long way behind.
Thanks Nev. I am a patient investor and prepared to ride the waves with companies I believe in. I've been accumulating BLT since 2005 and now that they're getting commercial traction that investment is treating me very well.
Im still well underwater with PEB but with this endorsement from KP I expect that situation to change significantly over the next 12-24 months. I can wait.
I lost a couple of grand so I got off lightly. That’s the thing about this sharemarket game people go off stocks and would not touch them with a 40 foot barge pole because they lost money. The past is the past and if the game has changed which I think it has then investors should look at the company with fresh eyes. Nothing would make me more happy then this company becoming very successful and making all investors a shed load of money. I hope this company goes from strength to strength and investors will not be making money at the expense of others which is what happens in the trading on cycles environment.
It is very interesting reading the comments on this thread. I suspect Balance is even looking at this one with renewed interest.
I haven't lost a cent with PEB because I've never sold a share. It's been a bit of a white-knuckle ride though and plenty of naysayers
with loud and frequently repeated negativity to cope with as well.
The company is not out of the woods yet, but acceptance by KP is sure to be the catalyst for more positive news over the next year or two.
PEB has a testing business model that requires tests to be shipped to home base, tested, then the results returned. Does PEB have the capacity to increase testing volume and is the return to home base model sustainable it testing demand increases substantially?
The money flows when the testing ramps up, shareholders need to focus on capacity and capability to meet testing demand, especially now when it looks like demand could increase significantly assuming final hurdles are overcome.
Lots of water left to go under the bridge imo, I’m not breaking out the champagne until I see the company doing something to meet ‘real’ sustained demand, not just a promise of demand, especially with a scaled testing model that is both unstated and on face value unable to scale to meet any significant growth in demand. This is the crux of moving from science to business. Whether PEB have the wherewithal to manage the transition from great science to successful business is far from proven.
Anyway, still great news and long overdue for patient shareholders, nice to see something really encouraging happen for a welcome change from years of disappointment.
Gltah
As we move from research development to commercialisation would it be wise to bring in a more business focused leader and put David head of research as he’s very talented on that front.
The new deal equals around 3% of the USA population and from memory that had signed up other firms many years ago.
How do we reduce the cash burn as $19 mill a year gives us 8 months left if those leads don’t yet monetise.
sold out at a profit years ago... did something just happen?